Reported about 7 hours ago
Merck has announced its planned $10 billion acquisition of Verona Pharma, expected to close in the fourth quarter of 2025. This strategic move aims to bolster Merck's product offerings for chronic obstructive pulmonary disease as it anticipates revenue declines from the expiration of patents for its cancer drug Keytruda. Meanwhile, discussions around potential tariffs on pharmaceuticals proposed by President Trump continue, with suggestions that such tariffs could be delayed.
Source: YAHOO